Key Business Approvals

The Board of Directors in their meeting (Serial No. 02/2026-27) held on Thursday, 13th August, 2026 approved the following:

  • Approved Standalone and Consolidated Un-Audited Financial Results for the quarter ended 30th June, 2026 along with Limited Review Reports
  • Reappointed Mr. Gurmeet Singh Bhatia (DIN: 00401697) as Whole-time Director for further period of three years with effect from 13th August, 2026 to 12th August, 2029, subject to member approval
  • Reappointed Mr. Gaurav Chhabra (DIN: 09603279) as Non-Executive Independent Director for second term of five years with effect from 14th May, 2027 to 13th May, 2032, subject to member approval
  • Approved Board's Report on Company Operations with required annexure, Corporate Governance Report, and Management Discussion and Analysis Report for year ended 31st March, 2026
  • Convening of 39th Annual General Meeting on Thursday, 24th September, 2026 at 11.30 AM through Video Conferencing or Other Audio-Visual Means

Financial Results Summary (Standalone)

Quarter Ended 30th June, 2026 (Reviewed) vs Comparative Periods:

Income Statement (₹ in Lakhs):

  • Income from Operations: ₹21,393.43 (vs ₹20,494.47 in Q1 FY26)
  • Other Income: ₹49.49 (vs ₹51.63 in Q1 FY26)
  • Total Revenue: ₹21,442.92 (vs ₹20,546.10 in Q1 FY26)
  • Total Expenses: ₹21,325.55 (vs ₹20,446.38 in Q1 FY26)
  • Profit before Tax: ₹117.37 (vs ₹99.72 in Q1 FY26)
  • Tax Expense: ₹35.79 (Current Tax: ₹34.24, Deferred Tax: ₹1.55)
  • Net Profit for Period: ₹81.58 (vs ₹71.46 in Q1 FY26)
  • Earnings Per Share (Basic/Diluted): ₹1.70 (vs ₹1.88/₹1.63 in Q1 FY26)

Balance Sheet Items:

  • Paid-up Equity Share Capital: ₹481.00 lakhs (Face Value ₹10 each)

Financial Results Summary (Consolidated)

Quarter Ended 30th June, 2026 (Reviewed) vs Comparative Periods:

Income Statement (₹ in Lakhs):

  • Income from Operations: ₹21,393.43
  • Other Income: ₹49.49
  • Total Revenue: ₹21,442.92
  • Total Expenses: ₹21,323.06
  • Profit before Tax: ₹119.86
  • Tax Expense: ₹36.36 (Current Tax: ₹35.01, Deferred Tax: ₹1.35)
  • Net Profit for Period: ₹83.50
  • Earnings Per Share (Basic/Diluted): ₹1.74
  • Non-controlling Interest: ₹0.33

Subsidiary Information

The consolidated financial statement includes financial figures of subsidiary company Puregene Biotech Limited (CIN: U01222MP1999PLC013303).

The subsidiary's unaudited financial results for quarter ended June 30, 2026, which were not reviewed by its auditors, reflect:

  • Total Revenue: ₹13.5 lakhs
  • Total Net Profit After Tax: ₹1.92 lakhs
  • Total Comprehensive Income: ₹1.92 lakhs

Management considers these figures not material to the Group.

Operational Context

The Company has been primarily engaged in Poultry Breeding & Farming activities only. There is no identifiable operating segment, hence no disclosure under IND AS 108 'Operating Segment'.

Previous Period Correction

The results published on 30th May 2026 contained an inadvertent error in consolidated figures for year ended 31st March, 2026 where depreciation was written under finance cost and vice versa. The error has been corrected with no impact on published profit figures.

Meeting Details

The Board Meeting commenced at 15:30 PM and concluded at 17:30 PM on August 13, 2026.